The Clinical Practice Committee of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine endorses the clinical practice guideline Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. The guideline serves as a useful bedside decision aid for clinicians managing adults with suspected and confirmed septic shock and sepsis-associated organ dysfunction.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310818PMC
http://dx.doi.org/10.1111/aas.14045DOI Listing

Publication Analysis

Top Keywords

septic shock
12
surviving sepsis
8
sepsis campaign
8
campaign international
8
international guidelines
8
guidelines management
8
management sepsis
8
sepsis septic
8
scandinavian society
8
society anaesthesiology
8

Similar Publications

Background: High levels of catecholamines are cardiotoxic and associated with stress-induced cardiomyopathies. Septic patients are routinely exposed to endogenously released and exogenously administered catecholamines, which may alter cardiac function and perfusion causing ischemia. Early during human septic shock, left ventricular ejection fraction (LVEF) decreases but normalizes in survivors over 7-10 days.

View Article and Find Full Text PDF

Malaria is highly prevalent in West and Central Africa. In the United States, most reported cases are due to immigration from endemic regions. Severe malaria caused by Plasmodium ovale is rare.

View Article and Find Full Text PDF

Patients with selective IgA deficiency could have various clinical presentations ranging from asymptomatic to severe respiratory or gastrointestinal tract infection, as well as autoimmune disease and allergic reactions. Selective IgA deficiency is relatively common in Caucasians, but it is rare in the Asian population, meaning it could be easily missed in the clinic. In this study, we report a 26-year-old man with a history of asthma and nephrotic syndrome.

View Article and Find Full Text PDF

In Light of the LANDI-SEP Trial: New Evidence or Double Jeopardy?

Indian J Crit Care Med

January 2025

Department of Critical Care Medicine, Ruby Hall Hospital, Pune, Maharashtra, India.

Datta PK, Sathe P, Bhattacharjee A, Kundu R. In Light of the LANDI-SEP Trial: New Evidence or Double Jeopardy? Indian J Crit Care Med 2025;29(1):84-85.

View Article and Find Full Text PDF

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.

Ther Adv Drug Saf

January 2025

Department of Pharmacy, Daping Hospital, Army Medical University, No. 10 Changjiang Branch Road, Yuzhong District, Chongqing 400042, China.

Background: Gilteritinib and midostaurin are FLT3 inhibitors that have made significant progress in the treatment of acute myeloid leukemia. However, their real-world safety profile in a large sample population is incomplete.

Objectives: We aimed to provide a pharmacovigilance study of the adverse events (AEs) associated with gilteritinib and midostaurin through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!